


The aim of the Fund is to provide a return by way of capital growth and income.
| Name | % Net Assets |
|---|---|
| United Kingdom Gilt 4.25 07/12/2040 | 2.0% |
| Bundesschatzanweisungen 0.25 13/12/2013 | 1.9% |
| GlaxoSmithKline PLC | 1.7% |
| Royal Dutch Shell PLC | 1.5% |
| AstraZeneca PLC | 1.3% |
| BT Group PLC | 1.2% |
| British American Tobacco PLC | 1.1% |
| United Kingdom Gilt 5.25 07/06/2012 | 1.1% |
| BG Group PLC | 1.0% |
| Unilever PLC | 0.9% |
| Key | % Net Assets |
|---|---|
| 2.0% | |
| 1.9% | |
| 1.7% | |
| 1.5% | |
| 92.9% |
| Date | 09-Apr-2021 |
|---|---|
| Bid | 128.00p |
| Offer | 128.00p |
| Currency | GBP |
| Change | 0.100p |
| % | 0.08% |
| YTD change | 128.00p |
| YTD % | n/a |
| Fund Inception | 16/10/2002 |
|---|---|
| Fund Manager | Quentin Fitzsimmons |
| TER | 1.54 (30-Mar-2012) |
| Minimum Investment | |
|---|---|
| Initial | £2000 |
| Additional | n/a |
| Savings | n/a |
| Charges | |
|---|---|
| Initial | 3.75% |
| Annual Mang't | 0.25% |
| Exit | n/a |
| Name | % |
|---|---|
| Standard deviation | 0.01 |
| Sharpe ratio | 0.09 |
You are here: research